Trigeminal Neuralgia Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Trigeminal Neuralgia Treatment Market |
Trigeminal Neuralgia (TN) is a debilitating condition characterized by
intense, electric shock-like pain in the face. The pain is often triggered by
even the slightest stimulation of the facial area, such as brushing teeth,
touching the face, or even talking. It affects approximately 4-5 people per
100,000 and is more common in women and people over 50 years of age. TN is a
chronic condition that can significantly reduce a person's quality of life and
ability to carry out daily activities. Treatment for TN involves a range of medications,
surgery, and alternative therapies, and the global market for TN treatment is
expanding rapidly.
The global Trigeminal Neuralgia Treatment Market is driven by factors such as increasing prevalence of TN, rising geriatric population, and increasing research and development activities. The market is expected to grow at a CAGR of 5.85% during the forecast period of 2022 to 2028, reaching USD 1.65 billion by 2028.
One of the key drivers
of the Trigeminal
Neuralgia Treatment Market is the increasing prevalence of Trigeminal Neuralgia. As the world's
population continues to age, the number of people with TN is expected to rise.
The disease is more common in people over the age of 50, and as the global
population ages, the number of people in this age group is expected to
increase. In addition, the rising prevalence of chronic diseases such as
multiple sclerosis, which is a risk factor for TN, is also contributing to the
growth of the Trigeminal Neuralgia Treatment Market.
Another driver of the Trigeminal Neuralgia Treatment Market is the increasing geriatric population. Older people are more likely to develop TN, and as the world's population ages, the demand for TN treatment is expected to increase. The elderly are also more likely to suffer from chronic pain conditions, which can make TN symptoms worse. As a result, there is a growing need for effective and safe TN treatments for older adults.
The development of the
Bruxism
Therapy Market may be constrained by the availability of
complementary therapies including exercise, yoga, and meditation. The Bruxism Therapy Market is anticipated
to reach US$ 1,143.1 million in 2022 and grow at a 6.6% CAGR during the
forecast period (2022-2030).
Top Manufacturers involved are Allergan Plc, Merz Pharma GmbH & Co., Biogen, Inc., Merz Pharma GmbH & Co., Abbott Laboratories, Trigemina Inc., Pfizer Inc., Novartis, and GlaxoSmithKline Plc.
Comments
Post a Comment